New

Delfi Diagnostics

The AI engine Fit Assessment

Beta

The company will be attending ViVE 2025 Event

Blurb

Delfi Diagnostics detects cancer early, when it is most curable, using high precision non-invasive blood tests.

HQ Location

Baltimore (United States)

Founded

2019

Employees

51 - 200

Total funding raised

$330.50M

Last Funding Event

Series B, $225.00M, July 18, 2022

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M

Delfi Diagnostics detects cancer early, when it is most curable, using high-precision non-invasive blood tests. It uses artificial intelligence and genome sequencing to detect unique patterns of DNA fragmentation in the blood of patients. The company was founded in 2019 and is based in Baltimore, Maryland.